CN1763018A - Oxazolidinone analog compound - Google Patents
Oxazolidinone analog compound Download PDFInfo
- Publication number
- CN1763018A CN1763018A CN 200510015288 CN200510015288A CN1763018A CN 1763018 A CN1763018 A CN 1763018A CN 200510015288 CN200510015288 CN 200510015288 CN 200510015288 A CN200510015288 A CN 200510015288A CN 1763018 A CN1763018 A CN 1763018A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- fluorine
- chlorine
- group
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is oxazolidone compound in the structure as shown or its pharmaceutically acceptable salt, and their use as medicine, especially as antibacterial medicine.
Description
Technical field
The invention belongs to medical technical field, or rather, relate to that a class has the compound of anti-microbial effect and as the purposes of antibacterials.
Background technology
In recent years; the resistant organism development of all kinds of microbiotic and antiseptic-germicide rapidly; for example: methicillin-resistant staphylococcus aureus (MRSA), methicillin-resistant staphylococcus epidermidis (MRSE), penicillin resistant streptococcus pneumoniae (PRSP), multi-drug resistant tubercule bacillus; especially the appearance of vancomycin-resistant enterococcus (VRE); cause difficulty to clinical treatment; after the bacterium contact antibacterials, morph, obtain resistance by plasmid or karyomit(e) mediation.At present, consistent think mainly contain four kinds of mechanism of action, be respectively: produce antibiotic enzyme, deactivation antibiotic; Antibacterials are not replied in the target site variation; Change the outer permeability of film, blocking drugs enters; Enhancing effluxes, and quickens to pump to enter intravital medicine.Because these drug-fast bacteria infections of the still difficult effectively control of existing medicine impel Pharmaceutical Chemist to make great efforts development novel anti drug tolerant bacteria medicine, design and screening have the new antimicrobial drug of new chemical structure, new role mechanism or new role target position.
Oxazolidine ketone antiseptic-germicide is the complete synthesis antiseptic-germicide of chemistry, and the gram-positive microorganism and the mycobacterium tuberculosis infection that are used for the treatment of anti-multiple medicine demonstrate fabulous prospect, have become a class antibacterial agent at present.
The oxazolidone compounds has seen following document:
EP311090 discloses the N-Fang oxazolidinone compounds with anti-microbial effect; EP609905 discloses 3-(nitrogen replaces) phenyl-5-β-amido Jia Ji oxazolidine-2-ketone compounds; CN1121919A discloses Wu unit heteroaryl-oxazolidinones; WO93/23384 discloses diazine (piperazine) the Bu Fen De oxazolidone and they purposes as biocide that contains replacement.WO93/09103 discloses substituted aryl and heteroaryl-phenyl-oxazolidones as biocide.WO90/02744 disclose as 5 of biocide '-indolinyl-5 β-amido methyl oxazolidinone, 3-(condensed ring replaces) phenyl-5 β-amido methyl oxazolidinone, and 3-(nitrogen replaces)-phenyl-5 β-amido methyl oxazolidinone.EP352781 discloses the phenyl oxazolidinones of phenyl and pyridyl replacement.EP316594 discloses the Ben Yi Xi oxazolidinone that 3-replaces.EP312000 discloses the phenyl oxazolidinones that phenyl methyl replaces.
Other reference discloses Ge kind various kinds De oxazolidone compounds, comprising: J.Med.Chem., 32,1673-81 (198); J.Med.Chem., 33,2569-78 (1990); Tetrahedron, 45,1323-26 (1989); J.Med.Chem., 35,1156 (1992); US4,801,600; US4,128,654; US4,250,318; US5,164,510; US5,523,403; US5,736,545; US5,981,528; US6,239,152B1; EP0657440; EP0694544; EP0738726; WO94/01110; WO95/07271; WO97/14690; WO97/37980; WO98/01447.
Summary of the invention
The invention discloses novel oxazolidinone derivatives and pharmacy acceptable salt thereof, and they are as the application of medicine, particularly as the application of antibacterials.
The present invention relates to the compound and the pharmacy acceptable salt thereof of general formula (I) structure.
R
1：
(a) amino (when X is NH);
(b)-NH-R
5；
R wherein
5Be C
1-C
8Alkyl, this alkyl can at random be replaced by following one or more group: fluorine, chlorine, hydroxyl, itrile group, carboxyl, amino, nitro, C
1-C
8Alkoxyl group, C
1-C
8Acyl group, phenyl, substituted-phenyl is by five yuan, hexa-member heterocycle of sulphur, oxygen, nitrogen heteroatom replacement;-CO-R
6Or-SO
2-R
7, R wherein
6, R
7Be C
1-C
8Alkyl or by fluorine, chlorine, hydroxyl, the C that itrile group replaces
1-C
8Alkyl; By chlorine, fluorine, C
1-C
6Alkyl, C
1-C
8Alkoxyl group, hydroxyl, itrile group, carboxyl, amino, the single, double or polysubstituted aryl of nitro.
R wherein
8, R
9Be hydrogen at the same time or separately, C
1-C
8Alkyl, this alkyl can be replaced by following one or more groups arbitrarily: fluorine, chlorine, hydroxyl, C
1-C
8Alkoxyl group, amino, C
1-C
8Alkylamino, C
1-C
8Dialkyl amido.Work as R
9Be H, then R
8During for aryl, this aryl can be replaced by following one or more group: C
1-C
6Alkyl, C
1-C
6Alkoxyl group, fluorine, chlorine, itrile group, carboxyl, amino, hydroxyl; If heterocyclic aryl can be five rings, the six ring heterocyclic aryls of sulfur-bearing, oxygen, nitrogen.
(d)-N＝R
10；
R wherein
10Be C
3-C
6Cycloalkyl or by C
1-C
3Alkyl is by the C of hydroxyl, fluorine, chlorine replacement
3-C
6Cycloalkyl contains the triatomic ring, tetra-atomic ring, five-ring, the six-ring that are replaced by sulphur, oxygen, nitrogen heteroatom, and this ring texture can be replaced by following one or more groups: hydroxyl, fluorine, chlorine, C
1-C
4Alkyl, C
1-C
4Alkoxyl group and by fluorine, the C that chlorine replaces
1-C
4Alkyl and C
1-C
4Alkoxyl group, phenyl, fluorine, chlorine, methyl, fluoro methyl, methoxyl group, single or disubstituted phenyl.
R
2, R
3: be hydrogen at the same time or separately, fluorine, chlorine, nitro, C
1-C
8The straight or branched alkyl, this alkyl can at random be replaced by following one or more group: fluorine, chlorine, hydroxyl, methylol, itrile group, C
1-C
6Alkoxyl group.
R
4: can be C
1-C
8Alkyl, this alkyl can at random be replaced by following one or more group: fluorine, chlorine, hydroxyl, itrile group, carboxyl, amino, nitro, C
1-C
8Alkoxyl group, C
1-C
8Acyl group, phenyl, substituted-phenyl is by five yuan, hexa-member heterocycle of sulphur, oxygen, nitrogen heteroatom replacement;-CO-R
11Or-SO
2-R
12, R wherein
11, R
12Be C
1-C
8Alkyl or by fluorine, chlorine, hydroxyl, the C that itrile group replaces
1-C
8Alkyl; By chlorine, fluorine, C
1-C
6Alkyl, C
1-C
8Alkoxyl group, hydroxyl, itrile group, carboxyl, amino, the single, double or polysubstituted aryl of nitro.
X：NH，S。
Y：CH，N。
Z:CH, N, O, S is O wherein, during S, R
4Do not exist.
m，n：1～3。
C of the present invention
1-C
8The straight or branched alkyl comprises methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, amyl group, isopentyl or the like.
Described C
1-C
3Alkyl or chlorine, fluorine replace C
1-C
3Alkyl can be methyl, ethyl, propyl group, chloroethyl, fluoro ethyl; C
1-C
3Alkoxyl group or chlorine, fluorine list or disubstituted C
1-C
3Alkoxyl group; C
1-C
8Alkoxyl group can be methoxyl group, oxyethyl group, propoxy-, butoxy, isobutoxy, chloroethoxy, chlorine propoxy-, 1,1-dichloro propoxy-, 1-fluoro-2-chlorine propoxy-or the like.
Described C
1-C
8Alkylamino, C
1-C
8Replace alkylamino, C
1-C
8Dialkyl amido, C
1-C
8Replacing dialkyl amido can be ethylamino, third amino, hydroxyethylamino, two hydroxyethylaminos or the like.
Described C
2-C
8Alkyloyl such as ethanoyl, propionyl, butyryl radicals, isobutyryl or the like.
Described C
3-C
6Cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or the like.
The heteroatomic triatomic ring of described replacement, tetra-atomic ring, five-ring, six-ring, heteroatoms is selected from O, S, N, can be N-methyl piperidine-4-base, N-ethylpiperidine-4-base, N-sec.-propyl piperidin-4-yl, 2,2,6,6-tetramethyl piperidine-4-base, tetramethylene sulfide-3-base, tetrahydrofuran (THF)-4-base, tetrahydric thiapyran-4-group or the like.
More desirable compound and code thereof are:
L1:(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-aminoguanidine hydriodate
L2:(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-cyclohexylidene base aminoguanidine
L3:(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[(4-sec.-propyl) benzene methene] aminoguanidine
L4:(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[(2-methyl-2-phenyl) ethylidene] aminoguanidine
L5:(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[2-benzo cyclohexylidene] aminoguanidine
L6:(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[(5-methyl) thenylidene] aminoguanidine
L7:(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[(4-hydroxyl) benzene methene] aminoguanidine
L8:(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[4-chlorobenzene methene] aminoguanidine
L9:(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[2-benzo cyclohexylidene] thiosemicarbazide
L10:(S)-and N-[[3-[3-fluoro-4-piperidyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-cyclohexylidene base aminoguanidine
L11:(S)-and N-[[3-[3-fluoro-4-piperidyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[2-benzo cyclohexylidene] aminoguanidine
L12:(S)-and N-[[3-[3-fluoro-4-piperidyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[(5-methyl) thenylidene] aminoguanidine
L13:(S)-and N-[[3-[3-fluoro-4-piperidyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[(4-hydroxyl) benzene methene] aminoguanidine
L14: embodiment 14 (S)-N-[[3-[3-fluoro-4-piperidyl] phenyl]-2-oxo-5-oxazolidinyl] methyl)-N '-[furfurylidene] aminoguanidine
Compound or its pharmacy acceptable salt with formula I structure of the present invention means: The compounds of this invention and mineral acid, organic acid salify, particularly preferred salt is: hydrochloride, hydrobromate, hydriodate, vitriol, hydrosulfate, phosphoric acid salt, acetate, propionic salt, butyrates, lactic acid salt, mesylate, tosilate, maleate, benzoate, succinate, tartrate, Citrate trianion, fumarate, taurate or the like.As described salt, they can also be the salt that forms with conventional alkali, for example an alkali metal salt.
The preparation of pharmaceutical compositions of The compounds of this invention is as follows: use standard and conventional technology; acceptable solid or liquid vehicle are combined, and make it at random to combine and be prepared into particulate or microballoon with acceptable auxiliary and vehicle on the technology of pharmaceutics.Solid dosage comprises tablet, discrete particles, capsule, slow releasing tablet, sustained release pellet or the like.Solid carrier can be at least a material, and it can serve as thinner, flavouring agent, solubilizing agent, lubricant, suspension agent, tackiness agent, disintegrating agent and coating agent.Inert solid carrier comprises trimagnesium phosphate, Magnesium Stearate, smoothers sugar, lactose, pectin, propylene glycol, Polysorbate 80, dextrin, starch, gelatin, cellulose substances for example methylcellulose gum, Microcrystalline Cellulose, low melt point paraffin, polyoxyethylene glycol, N.F,USP MANNITOL, theobroma oil etc.Liquid dosage form comprises solvent, suspension for example injection, pulvis or the like.
The amount of the active ingredient that contains in pharmaceutical composition and the unit dosage form (The compounds of this invention) can be according to patient's the state of an illness, specific being applied of situation of diagnosis, the amount of used compound or concentration are regulated in the scope of a broad, usually, the weight range of active compound is 0.5%～90% (weight) of composition.Another preferred range is 0.5%-70%.
Further specify the restraining effect of The compounds of this invention below by bacteriostatic experiment to bacterium.
1, experiment material
(1) substratum: microorganism identification substratum PH7.9 ± 0.1 Beijing, three medicine scientific and technological development company lot numbers: 020425
(2) bacterial classification: bacillus pumilus CMCC 63202, staphylococcus epidermidis CMCC26069, blue pus organism CMCC10211, klebsiella pneumoniae CMCC 46117, colon bacillus CMCC 44113, and above bacterial classification is all purchased in Nat'l Pharmaceutical ﹠ Biological Products Control Institute.
2, experimental technique
(1) sample and code:
Sample: L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, L11, L12, L13, L14.
Compound method: take by weighing above-mentioned each sample of about 2mg respectively, in the 50ml volumetric flask, after a spot of DMF dissolving, add to scale with distilled water, concentration is 10 μ mol/L, and filtration sterilization is with the centrifuge tube packing of 2ml.
(2) preparation of culture dish:
Microorganism identification substratum I after a certain amount of sterilization (making substratum thickness is 3mm), be chilled to 48-50 ℃, add an amount of bacterium liquid (bacteria concentration is 0.1%) respectively, pour in the culture dish of the level of mixing up, carefully drive bubble away, after the culture medium solidifying, carry out mark in the graze cattle position of Tianjin cup of needs, standby.
(3) mensuration of sample
At interval 2.5-3cm places the Oxford cup on culture dish, notes correspondingly with mark position, gets each sample 50 μ l application of sample with micro sample adding appliance, is 2-3 and manages again, carries out the application of sample record, is placed on 37 ℃ of CO
2After cultivating 16-18h in the incubator, use the vernier caliper measurement antibacterial circle diameter.
3, experimental result:
The result shows that compound has bacteriostatic action to staphylococcus epidermidis, streptococcus aureus, streptococcus pneumoniae etc., and intestinal bacteria, Pseudomonas aeruginosa etc. are not seen bacteriostatic action, points out the compound of this class formation to have anti-G
+The effect of bacterium.
| Staphylococcus epidermidis | Streptococcus aureus | Streptococcus pneumoniae | Intestinal bacteria | Pseudomonas aeruginosa | |
| L1： | - | - | - | - | - |
| L2： | + | + | - | - | - |
| L3： | + | + | + | - | - |
| L4： | + | + | + | - | - |
| L5： | + | + | + | - | - |
| L6： | + | + | + | - | - |
| L7： | - | - | - | - | - |
| L8： | + | + | + | - | - |
| L9： | + | + | + | - | - |
| L10 | + | + | - | - | - |
| L11 | + | + | - | - | - |
| L12 | + | + | + | - | - |
| L13 | + | + | + | - | - |
| L14 | - | - | - | - | - |
+: bacteriostatic action is arranged;-: not seeing has bacteriostatic action
Embodiment:
The present invention is described further below in conjunction with embodiment, embodiment only is indicative, mean that never it limits the scope of the invention by any way, the compound of invention is through high performance liquid chromatography (HPLC), thin-layer chromatography (TLC), fusing point (m.p.) detects, can adopt subsequently nucleus magnetic resonance (
1HNMR/
13CNMR) etc. further prove conclusively its structure.
Needed intermediate in the experiment:
Amino substance 1 amino substance 2
Intermediate 1 intermediate 2
Intermediate 3 intermediates 4
Intermediate 5 intermediates 6
Intermediate 7 intermediates 8
Intermediate 9
The preparation of amino substance 1 is with reference to Journal of Medicinal Chemistry.1996.39 (3): 673～378. methods that provide, and amino substance 2 also can prepare as stated above, and this is to be familiar with this professional personage to understand.
Amino substance 1:R
f=0.38 (developping agent: dehydrated alcohol: triethylamine=30: 1); HPLC99.5%;
1HNMR (CDCl
3, 400Hz): δ 7.468 (dd, 1H, Ar-H), 7.147 (m, 1H, Ar-H), 6.924 (t, 1H, Ar-H), 4.655 (m, 1H, O-CH), 4.003 (t, 1H), 3.853 (m, 4H, CH
2OCH
2), 3.814 (t, 1H), 3.120 (dd, 1H), 3.047 (t, 4H, CH
2NCH
2), 2.981 (dd, 1H), 2.210 (s, 2H, NH
2).
Amino substance 2:R
f=0.23 (developping agent: dehydrated alcohol: triethylamine=30: 1); HPLC 99.2%;
1HNMR (DMSO, 400Hz): δ 7.173 (dd, 1H, Ar-H), 7.173 (dd, 1H, Ar-H), 7.028 (t, 1H, Ar-H), 4.573 (m, 1H, O-CH), 4.003 (t, 1H, CH-N), 3.806 (t, 1H, CH-N), 2.899 (m, 4H, CH
2O-CH
2), 2.841 (m, 2H, N-CH
2), 2.746 (m, 2H, NH
2), 1.631 (m, 4H ,-CH
2CH
2-), 1.513 (m, 2H ,-CH
2-).
Intermediate 1～7 prepares by following logical method:
With methyl iodide back flow reaction 4 hours in anhydrous methanol, reaction is finished Deng the mole Urea,amino-, cooling.Separate out white solid, filter, anhydrous methanol is washed, and gets S-methylamino isothiourea.m.p.133.5～134.4℃。
S-methylamino isothiourea reacts with equimolar pimelinketone, 4-isopropyl benzene formaldehyde, 2-methyl phenylacetaldehyde, 2-benzo pimelinketone, 5-thiotolene formaldehyde, p-Hydroxybenzaldehyde, furtural in methyl alcohol, makes corresponding intermediate 1, intermediate 2, intermediate 3, intermediate 4, intermediate 5, intermediate 6, intermediate 7.
Intermediate 8, intermediate 9 can prepare by following method:
Equimolar hydrazine hydrate (80%), dithiocarbonic anhydride, potassium hydroxide (being dissolved in the water of 4 times of amounts) added in the Virahol, in 5～10 ℃ of reactions 4 hours.Drip equimolar methyl iodide then, added in about 30 minutes, continue insulation reaction and placed 4 hours after 3 hours.Filter and promptly get diazanyl dithio methyl-formiate.m.p.82.0～82.4℃。
Above-mentioned diazanyl dithio methyl-formiate reacts with equimolar 4-chloro-benzaldehyde, α-benzo pimelinketone respectively at 40～50 ℃ in dehydrated alcohol, makes corresponding intermediate 8, intermediate 9.
| Intermediate | Fusing point (℃) | R f |
| Intermediate 1 intermediate 2 intermediates 3 intermediates 4 intermediates 5 intermediates 6 intermediates 7 intermediates 8 intermediates 9 | 76.5～77.5 80.1～80.7 72.5～73.9 192.1～193.2 158.0～159.7 do not survey 176.8～178.3 146.1～147.3 | 0.83 (absolute ethyl alcohol) 0.59 (petrol ether/ethyl acetate=2: 1) 0.82 (ethyl acetate) 0.79 (petrol ether/ethyl acetate=1: 3) 0.65 (petrol ether/ethyl acetate=1: 1) 0.58 (petrol ether/ethyl acetate=1: 1) 0.53 (petrol ether/ethyl acetate=1: 1) 0.31 (petrol ether/ethyl acetate=5: 1) do not surveyed |
Embodiment 1
(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-aminoguanidine hydriodate (L1)
With 1g (S)-N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methylamine (amino substance 1) and 0.8gS-methylamino isothiourea hydriodate put in the 10ml dehydrated alcohol and be warming up to backflow behind 40 ℃ of reaction 5～6h, insulation reaction 2～3h, filtered while hot, dry, white solid, m.p.208.2～209.4 ℃.
Embodiment 2
(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-cyclohexylidene base aminoguanidine (L2)
5g intermediate 1 and 2.5g amino substance 1 are put in the 50ml dehydrated alcohol; nitrogen protection is warming up to back flow reaction 3h, adds other 2.5g amino substance; back flow reaction 21h; solvent is to the greatest extent steamed in decompression, silica gel column chromatography (moving phase: dehydrated alcohol: triethylamine=30: 1), get solid; dry; m.p.144.4～145.7 ℃, and the TLC chromatography (developping agent: dehydrated alcohol: triethylamine=30: 1), product point R
fValue 0.38.
Become Citrate trianion: get above-mentioned product 1.5g, be dissolved in the 45ml dehydrated alcohol, be heated to backflow, add and wait mole citric acid, insulation reaction 30min.Reduce to room temperature, placed 12 hours.Separate out white solid, filter.Gained solid drying promptly gets its Citrate trianion, m.p.206～207.6 ℃.
Embodiment 3
(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[(4-sec.-propyl) benzene methene] aminoguanidine (L3)
1.2g intermediate 2 and 0.5g amino substance 1 are put in the 10ml dehydrated alcohol; nitrogen protection is warming up to back flow reaction 3h, adds other 0.5g amino substance; back flow reaction 2～3h; solvent is to the greatest extent steamed in decompression, silica gel column chromatography (moving phase: dehydrated alcohol: triethylamine=30: 1), get small amount of solid; dry; m.p.119.0～120.0 ℃, and the TLC chromatography (developping agent: dehydrated alcohol: triethylamine=30: 1), product point R
fValue 0.48.
Embodiment 4
(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[(2-methyl-2-phenyl) ethylidene] aminoguanidine (L4)
1.0g intermediate 3 and 0.5g amino substance 1 are put in the 10ml dehydrated alcohol; nitrogen protection is warming up to back flow reaction 3h, adds other 0.4g amino substance; back flow reaction 12h; solvent is to the greatest extent steamed in decompression, silica gel column chromatography (moving phase: dehydrated alcohol: triethylamine=30: 1), get solid; dry; m.p.65～85 ℃, and the TLC chromatography (developping agent: dehydrated alcohol: triethylamine=30: 1), product point R
fValue 0.48.
Embodiment 5
(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[2-benzo cyclohexylidene] aminoguanidine (L5)
1.2g intermediate 4 and 1.0g amino substance 1 are put in the 50ml dehydrated alcohol; nitrogen protection; back flow reaction 12h; solvent is to the greatest extent steamed in decompression, silica gel column chromatography (moving phase: dehydrated alcohol: triethylamine=30: 1), get solid; dry; m.p.182.0～182.5 ℃, and the TLC chromatography (developping agent: dehydrated alcohol: triethylamine=30: 1), product point R
fValue 0.44.
Embodiment 6
(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[(5-methyl) thenylidene] aminoguanidine (L6)
1.2g intermediate 5 and 1.1g amino substance 1 are put in the 50ml dehydrated alcohol; nitrogen protection; back flow reaction 17h; solvent is to the greatest extent steamed in decompression, silica gel column chromatography (moving phase: dehydrated alcohol: triethylamine=30: 1), get solid; dry; m.p.161.3～161.7 ℃, and the TLC chromatography (developping agent: dehydrated alcohol: triethylamine=30: 1), product point R
fValue 0.51.
Embodiment 7
(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[(4-hydroxyl) benzene methene] aminoguanidine (L7)
4g intermediate 6 and 5g amino substance 1 are put in the 50ml dehydrated alcohol; nitrogen protection; back flow reaction 17h; solvent is to the greatest extent steamed in decompression, silica gel column chromatography (moving phase: dehydrated alcohol: triethylamine=30: 1), get solid; dry; m.p.182.4～182.9 ℃, and the TLC chromatography (developping agent: dehydrated alcohol: triethylamine=30: 1), product point R
fValue 0.30.
Become sodium salt: get above-mentioned product 2g, be dissolved in the 60ml methyl alcohol, frozen water is cooled to 10～15 ℃, stirs the aqueous sodium hydroxide solution of dropping 30% down, to the most solvent of PH10 decompression steaming, and adding 35ml dehydrated alcohol/water (6/4, V/V) mixing solutions, be heated to backflow, filtered while hot is placed in the filtrate chamber.Filter, white solid, be drying to obtain its sodium salt, m.p.＞230 ℃.
Embodiment 8
(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[4-chlorobenzene methene] aminoguanidine (L8)
1g intermediate 8 and 1.3g amino substance 1 are put in the 20ml dehydrated alcohol; nitrogen protection; back flow reaction 17h; solvent is to the greatest extent steamed in decompression, silica gel column chromatography (moving phase: ethyl acetate: sherwood oil: triethylamine=1: 1: 0.05), get solid; dry; m.p.187.3～188.2 ℃, and the TCL chromatography (developping agent: ethyl acetate: sherwood oil: triethylamine=1: 1: 0.05), product point R
fValue 0.76.
Embodiment 9
(S)-and N-[[3-[3-fluoro-4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[2-benzo cyclohexylidene] thiosemicarbazide (L9)
1.5g intermediate 9 and 1.0g amino substance 1 are put in the 25ml dehydrated alcohol; nitrogen protection; back flow reaction 17h; solvent is to the greatest extent steamed in decompression, silica gel column chromatography (moving phase: ethyl acetate: sherwood oil: triethylamine=4: 3: 0.05), get solid; dry; m.p.153.3～154.8 ℃, and the TLC chromatography (developping agent: ethyl acetate: sherwood oil: triethylamine 1: 1: 0.05), product point R
fValue 0.80.
Embodiment 10
(S)-and N-[[3-[3-fluoro-4-piperidyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-cyclohexylidene base aminoguanidine (L10)
With 1g intermediate 1 and 2.8g (S)-N-[[3-[3-fluoro-4-piperidyl] phenyl]-2-oxo-5-oxazolidinyl] methylamine (amino substance 2) puts in the 150ml dehydrated alcohol behind 50 ℃ of reaction 5h and is warming up to back flow reaction 3h, TLC chromatography (developping agent: dehydrated alcohol: product point R triethylamine=30: 1)
fValue 0.65, column chromatography are collected Rf value 0.65 product point liquid, after liquid is dissolved among the DMF, add entry and generate to there being solid, filter, drying gets white solid, m.p.77.4～78.7 ℃.
Embodiment 11
(S)-and N-[[3-[3-fluoro-4-piperidyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[2-benzo cyclohexylidene] aminoguanidine (L11)
1.5g intermediate 4 and 1.5g amino substance 2 put in the 150ml dehydrated alcohol behind 50 ℃ of reaction 5h, be warming up to back flow reaction 3h, TLC chromatography (developping agent: dehydrated alcohol: product point R triethylamine=30: 1)
fValue 0.60, column chromatography are collected Rf value 0.60 product point liquid, after liquid is dissolved among the DMF, add entry and generate to there being solid, filter, drying gets white solid.
Embodiment 12
(S)-and N-[[3-[3-fluoro-4-piperidyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[(5-methyl) thenylidene] aminoguanidine (L12)
1.5g intermediate 5 and 2g amino substance 2 put in the 150ml dehydrated alcohol behind 50 ℃ of reaction 5h, be warming up to back flow reaction 3h, TLC chromatography (developping agent: dehydrated alcohol: product point R triethylamine=30: 1)
fValue 0.55, column chromatography are collected Rf value 0.55 product point liquid, after liquid is dissolved among the DMF, add entry and generate to there being solid, filter, drying gets white solid
Embodiment 13
(S)-and N-[[3-[3-fluoro-4-piperidyl] phenyl]-2-oxo-5-oxazolidinyl] methyl-N '-[(4-hydroxyl) benzene methene] aminoguanidine (L13)
2g intermediate 6 and 2.5g amino substance 2 put in the 150ml dehydrated alcohol behind 50 ℃ of reaction 5h, be warming up to back flow reaction 3h, TLC chromatography (developping agent: dehydrated alcohol: product point R triethylamine=30: 1)
fValue 0.60, column chromatography are collected Rf value 0.60 product point liquid, after liquid is dissolved among the DMF, add entry and generate to there being solid, filter, drying gets white solid.
Become sylvite: get above-mentioned product 1g, be dissolved in the 87ml anhydrous methanol, frozen water is cooled to 10～15 ℃, stirs the potassium hydroxide aqueous solution of dropping 25% down, to PH11.Solvent is to the greatest extent steamed in decompression, add 26ml dehydrated alcohol/water (6/4, V/V) mixing solutions is heated to backflow, be incubated ten minutes, filtered while hot, white solid is separated out in placement filtrate chamber in, filtration is drying to obtain its sylvite, m.p.＞235 ℃.
Embodiment 14
(S)-and N-[[3-[3-fluoro-4-piperidyl] phenyl]-2-oxo-5-oxazolidinyl] methyl)-N '-[furfurylidene] aminoguanidine (L14)
1.7g intermediate 7 and 1.0g amino substance 2 put in the 150ml dehydrated alcohol behind 50 ℃ of reaction 5h, be warming up to back flow reaction 3h, TLC chromatography (developping agent: dehydrated alcohol: product point R triethylamine=30: 1)
fValue 0.60, column chromatography are collected Rf value 0.60 product point liquid, after liquid is dissolved among the DMF, add entry and generate to there being solid, filter, drying gets white solid.
In order to explain enforcement of the present invention more fully, provide following example of formulations.These embodiment explain rather than limit the scope of the invention.Preparation can adopt any one compound among the present invention as activeconstituents.
Embodiment 1
Every tablet preparation that contains the 100mg activeconstituents:
The mg/ sheet
L-3 100
Lactose 50
Microcrystalline Cellulose 80
Starch 50
Hydroxyl methylcellulose 40
Magnesium Stearate 5
With activeconstituents, lactose, starch, Microcrystalline Cellulose are crossed 100 mesh sieves, and abundant mixing, the 2% hydroxyl methylcellulose aqueous solution joined in the above-mentioned mixed powder mix, cross 20 mesh sieve system softwoods, make wet granular in 45-55 ℃ of drying, carboxymethylstach sodium, Magnesium Stearate are joined compressing tablet in the above-mentioned dried particles.
Embodiment 2
Every capsule contains the capsular of 100mg activeconstituents and is prepared as follows:
Consumption/capsule weight concentration (%)
L-4 100mg 30.0
Polyoxyethylene dehydration sorb 0.05mg 0.02
The sugar alcohol monoleate
Starch 250mg 69.98
Amount to 350.05mg 100.00
Claims (6)
1, the compound or its pharmacy acceptable salt that have formula (I) structure:
R wherein
1:
(a) amino (when X is NH);
(b)-NH-R
5；
R wherein
5Be C
1-C
8Alkyl, this alkyl can at random be replaced by following one or more group: fluorine, chlorine, hydroxyl, itrile group, carboxyl, amino, nitro, C
1-C
8Alkoxyl group, C
1-C
8Acyl group, phenyl, substituted-phenyl is by five yuan, hexa-member heterocycle of sulphur, oxygen, nitrogen heteroatom replacement;-CO-R
6Or-SO
2-R
7, R wherein
6, R
7Be C
1-C
8Alkyl or by fluorine, chlorine, hydroxyl, the C that itrile group replaces
1-C
8Alkyl; By chlorine, fluorine, C
1-C
6Alkyl, C
1-C
8Alkoxyl group, hydroxyl, itrile group, carboxyl, amino, the single, double or polysubstituted aryl of nitro;
R wherein
8, R
9Be hydrogen at the same time or separately, C
1-C
8Alkyl, this alkyl can be replaced by following one or more groups arbitrarily: fluorine, chlorine, hydroxyl, C
1-C
8Alkoxyl group, amino, C
1-C
8Alkylamino, C
1-C
8Dialkyl amido; Work as R
9Be H, then R
8During for aryl, this aryl can be replaced by following one or more group: C
1-C
6Alkyl, C
1-C
6Alkoxyl group, fluorine, chlorine, itrile group, carboxyl, amino, hydroxyl; If heterocyclic aryl can be five rings, the six ring heterocyclic aryls of sulfur-bearing, oxygen, nitrogen;
(d)-N＝R
10；
R wherein
10Be C
3-C
6Cycloalkyl or by C
1-C
3Alkyl is by the C of hydroxyl, fluorine, chlorine replacement
3-C
6Cycloalkyl contains the triatomic ring, tetra-atomic ring, five-ring, the six-ring that are replaced by sulphur, oxygen, nitrogen heteroatom, and this ring texture can be replaced by following one or more groups: hydroxyl, fluorine, chlorine, C
1-C
4Alkyl, C
1-C
4Alkoxyl group and by fluorine, the C that chlorine replaces
1-C
4Alkyl and C
1-C
4Alkoxyl group, phenyl, fluorine, chlorine, methyl, fluoro methyl, methoxyl group, single or disubstituted phenyl;
R
2, R
3: be hydrogen at the same time or separately, fluorine, chlorine, nitro, C
1-C
8The straight or branched alkyl, this alkyl can at random be replaced by following one or more group: fluorine, chlorine, hydroxyl, methylol, itrile group, C
1-C
6Alkoxyl group;
R
4: can be C
1-C
8Alkyl, this alkyl can at random be replaced by following one or more group: fluorine, chlorine, hydroxyl, itrile group, carboxyl, amino, nitro, C
1-C
8Alkoxyl group, C
1-C
8Acyl group, phenyl, substituted-phenyl is by five yuan, hexa-member heterocycle of sulphur, oxygen, nitrogen heteroatom replacement;-CO-R
11Or-SO
2-R
12, R wherein
11, R
12Be C
1-C
8Alkyl or by fluorine, chlorine, hydroxyl, the C that itrile group replaces
1-C
8Alkyl; By chlorine, fluorine, C
1-C
6Alkyl, C
1-C
8Alkoxyl group, hydroxyl, itrile group, carboxyl, amino, the single, double or polysubstituted aryl of nitro;
X：NH，S；
Y：CH，N；
Z:CH, N, O, S is O wherein, during S, R
4Do not exist;
m，n＝1～3。
2, formula I compound as claimed in claim 1, wherein R
2During for hydrogen or fluorine, R
3Be fluorine or hydrogen.
3, formula I compound as claimed in claim 1, wherein when m was 1～3, n was 3～1.
4, formula I compound as claimed in claim 1, wherein pharmacy acceptable salt means The compounds of this invention and sour salify, comprises mineral acid and organic acid; With the alkali salify, alkali is alkali-metal oxyhydroxide.
5, a kind of pharmaceutical composition, it contains the defined formula I compound of claim 1 and pharmaceutically acceptable one or more vehicle.
6, the described formula I compound of claim 1 is used for the treatment of the application aspect the medicine of sensitive bacterial infected patient in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510015288 CN1763018B (en) | 2005-09-30 | 2005-09-30 | Oxazolidinone analog compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510015288 CN1763018B (en) | 2005-09-30 | 2005-09-30 | Oxazolidinone analog compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1763018A true CN1763018A (en) | 2006-04-26 |
| CN1763018B CN1763018B (en) | 2012-11-21 |
Family
ID=36747366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510015288 Expired - Fee Related CN1763018B (en) | 2005-09-30 | 2005-09-30 | Oxazolidinone analog compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1763018B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010504368A (en) * | 2006-09-25 | 2010-02-12 | ウォックハート リサーチ センター | Substituted piperidinophenyloxazolidinone |
| CN101220002B (en) * | 2007-12-28 | 2011-07-13 | 天津药物研究院 | Oxazolidinone compound as antimicrobial |
| CN102164919A (en) * | 2008-10-10 | 2011-08-24 | 埃科特莱茵药品有限公司 | Oxazolidinyl antibiotics |
| CN103232446A (en) * | 2013-05-17 | 2013-08-07 | 天津药物研究院 | Oxazolidinone derivative crystal form II and preparation method and application thereof |
| CN103467358A (en) * | 2013-08-15 | 2013-12-25 | 蚌埠丰原医药科技发展有限公司 | Preparation method for tegaserod maleate |
-
2005
- 2005-09-30 CN CN 200510015288 patent/CN1763018B/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010504368A (en) * | 2006-09-25 | 2010-02-12 | ウォックハート リサーチ センター | Substituted piperidinophenyloxazolidinone |
| CN101220002B (en) * | 2007-12-28 | 2011-07-13 | 天津药物研究院 | Oxazolidinone compound as antimicrobial |
| CN102164919A (en) * | 2008-10-10 | 2011-08-24 | 埃科特莱茵药品有限公司 | Oxazolidinyl antibiotics |
| CN103232446A (en) * | 2013-05-17 | 2013-08-07 | 天津药物研究院 | Oxazolidinone derivative crystal form II and preparation method and application thereof |
| CN103232446B (en) * | 2013-05-17 | 2015-09-23 | 天津药物研究院 | Yi Zhong oxazolidinone derivative crystal form II and its production and use |
| CN103467358A (en) * | 2013-08-15 | 2013-12-25 | 蚌埠丰原医药科技发展有限公司 | Preparation method for tegaserod maleate |
| CN103467358B (en) * | 2013-08-15 | 2015-09-02 | 蚌埠丰原医药科技发展有限公司 | The preparation method of Zelnorm |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1763018B (en) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2414469C2 (en) | Novel oxazolidinone derivatives | |
| CN1073112C (en) | Possibly substituted 8-cyano-cyclopropyl-7-(2,8-diazabicyclo-[4,3,0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives | |
| CN1690047A (en) | 9-substituted minocycline compounds | |
| CN1649582A (en) | Amino-methyl substituted tetracycline compounds | |
| CN1154644C (en) | Oxazolidinone derivatives and pharmaceutical compositions | |
| CN1391572A (en) | Oxazolidinones having sulfoximine functionality and their use as antimicrobial agents | |
| HRP20050658A2 (en) | Antibacterial indolone oxazolidinones, intermediates for their preparation and pharmaceutical compositions containing them | |
| HUE033711T2 (en) | Compositions and methods for treating alcohol use disorders, pain and other diseases | |
| CN1395569A (en) | Oxazolidinone thioamides with piperazine amide substituents | |
| CN1763018A (en) | Oxazolidinone analog compound | |
| CN1106387C (en) | PDE IV inhibiting 2-cyanoiminoimidazole derivs. | |
| CN101016270B (en) | Substituted piperazinphenylisoxazoline derivative and use thereof | |
| CZ20022389A3 (en) | Esters of benzoic acid and oxazolidinones having hydroxyacetylpiperazine substituent | |
| CN1642543A (en) | Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections | |
| CN1237056C (en) | Oxazolidone compound, preparing method and use thereof | |
| CN101070308B (en) | Isoxazoline derivative and its use | |
| CN101096369B (en) | Oxazolidinone compound containing thiadiazoles groups and preparation method thereof | |
| CN101220000B (en) | Acyl chloride and sulfonyl chloride derivant, and uses thereof | |
| CN101619061A (en) | Cyanopyridyl-replaced oxazolidinone compound | |
| CN101220002B (en) | Oxazolidinone compound as antimicrobial | |
| JP6286536B2 (en) | New oxazolidinone antibacterial compounds | |
| CN1116301C (en) | Tetracydic fluoquinolone carboxylic acid, its preparing process and medicinal composition containing it as active component | |
| CN1829516A (en) | S 2-'4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatement of obesity | |
| CN101560209A (en) | Oxazolidinone compound containing pyridine and preparation method thereof | |
| CN100336809C (en) | Peptide deformylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121121 Termination date: 20160930 |